Building a strong and resilient self-managed super fund (SMSF) portfolio requires careful stock selection, with a focus on quality businesses that can deliver steady growth over the long term.
While short-term market fluctuations can be unpredictable, investing in companies with robust fundamentals, strong industry positions, and attractive long-term prospects can help SMSF investors build wealth and achieve financial security in retirement.
When looking for ASX 200 shares to include in an SMSF, key factors to consider include earnings consistency, competitive advantages, and exposure to industries with long-term growth potential.
With that in mind, here are three super strong ASX 200 shares that analysts believe could be great additions to an SMSF portfolio right now. They are as follows:
Goodman Group (ASX: GMG)
The first strong ASX 200 share that could be a buy according to analysts right now is Goodman Group.
It is one of the world's leading integrated commercial and industrial property companies with a world-class portfolio of high-demand properties in key growth sectors such as data centres, e-commerce, and logistics.
This strategic focus has driven strong earnings growth over the years and analysts at Citi believe this can continue in the medium term.
It is for this reason that the broker recently put a buy rating and $40.00 price target on its shares.
James Hardie Industries plc (ASX: JHX)
James Hardie could be another strong ASX 200 share for SMSF investors to buy now.
Bell Potter is a big fan of the building materials company. This is due to the structural shift towards fibre cement in the United States, which it expects to support a multi-year runway for revenue and profit growth.
This is likely to be supported also by cyclical tailwinds from potential rate cuts.
Bell Potter currently has a buy rating and $63.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Finally, Goldman Sachs thinks that sleep disorder treatment company ResMed could be a strong ASX 200 share to buy in March for an SMSF.
It is bullish on the company due to robust Continuous Airway Pressure Therapy (CPAP) patient growth, which is being assisted by growing awareness on sleep apnoea.
It also expects ResMed to build on its number one global position and make further market share gains. Combined with an operating margin expansion, Goldman believes this will underpin double digit earnings growth through to at least FY 2027.
Goldman Sachs currently has a buy rating and $49.00 price target on its shares.
